PIK3CA and colorectal carcinoma: Despite the promising results reported by these two studies, there is some caveat to express: based on the stratification necessary, i.e., patients with PIK3CA mutated tumors and taking regularly aspirin, the numbers of patients is relatively small in both studies (60 and 45 patients, respectively) and prospective, large scale clinical trials are needed to confirm this data, highly relevant for the future management of patients with CRC.